Bispecific

Research Grade Bispecific Antibody Biosimilars

Our comprehensive collection of research-grade bispecific antibody biosimilars supports cutting-edge immunotherapy research and development. These advanced molecules are engineered to simultaneously bind two different antigens or epitopes, enabling novel therapeutic approaches in oncology and immunology research.

Product Range

Our portfolio includes biosimilars of leading bispecific antibodies, featuring CD20xCD3 targeting molecules (Glofitamab, Mosunetuzumab, Epcoritamab), CD3-engaging therapeutics (Blinatumomab), and novel dual-targeting antibodies for various therapeutic applications. Each product is manufactured to rigorous quality standards for research use.

Applications

• Cancer immunotherapy research
• T-cell engagement studies
• Protein-protein interaction analysis
• Drug development and screening
• Mechanism of action investigations
• Comparative binding studies

Quality Assurance

Every biosimilar in our catalog undergoes comprehensive characterization to ensure:

• Structural integrity
• Dual binding functionality
• Batch-to-batch consistency
• High purity standards
• Research-grade quality specifications

*For research use only. Not for diagnostic or therapeutic applications.*